Cardiology Trials Podcast
1) Special episode (ESC 2025: AQUATIC, VICTOR)
Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe
2) Special episode (ESC 2025: REBOOT-CNIC, BETAMI-DANBLOCK, DIGIT-HF)
Discussion of landmark trials presented at the European Society of Cardiology (ESC) congress 2025 Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe
3) Summary and discussion of BEST and SENIORS
For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe
4) Review of the A-HeFT trial
N Engl J Med 2004;351:2049-2057Background: Endothelial dysfunction, reduced nitric oxide availability, and increased oxidative stress occur in patients with heart failure and contribute to cardiac rem...Show More
5) Review of the CHARM-Alternative trial
THE LANCET 2003;362:772-776Background: Angiotensin converting enzyme inhibitors (ACEi) reduce mortality and morbidity in patients with systolic heart failure (see CONSENSUS and SOLVD trials). However,...Show More
6) Summary and discussion of Carvedilol Prospective Randomized Cumulative Survival Study, Val-HeFT, CHARM-Added and CIBIS-II
For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe
7) Review of the CIBIS II Trial
The Lancet Volume 353, Issue 9146 p9-13 January 02, 1999Background: Accumulating data at the time suggested functional benefits of antagonism of beta-adrenoreceptors in patients with heart failure. Mu...Show More
8) Review of the CHARM-Added trial
THE LANCET 2003;362:767-771Background: Angiotensin II which plays a role in ventricular remodeling and progression of heart failure can be produced by pathways independent of angiotensin convening enz...Show More
9) Review of the Val-HeFT trial
N Engl J Med 2001;345:1667-1675Background: Angiotensin II is a peptide hormone that is part of the renin–angiotensin–aldosterone system (RAAS). Angiotensin II is a potent vasoconstrictor and growth-st...Show More
10) Review of the Carvedilol Prospective Randomized Cumulative Survival Study
N Engl J Med 2001;344:1651-1658Background: The MERIT-HF trial demonstrated the efficacy of the selective beta blocker metoprolol CR/XL for well selected patients with chronic systolic heart failure wh...Show More